.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Harvard Business School
Johnson and Johnson
Mallinckrodt
Deloitte
Express Scripts
Fish and Richardson
Accenture
Federal Trade Commission
Boehringer Ingelheim

Generated: June 28, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021548

« Back to Dashboard
NDA 021548 describes LEXIVA, which is a drug marketed by Viiv Hlthcare and is included in two NDAs. It is available from four suppliers. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the LEXIVA profile page.

The generic ingredient in LEXIVA is fosamprenavir calcium. There are four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the fosamprenavir calcium profile page.

Summary for NDA: 021548

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details

Pharmacology for NDA: 021548

Mechanism of ActionHIV Protease Inhibitors
Cytochrome P450 3A4 Inhibitors
Cytochrome P450 3A4 Inducers
P-Glycoprotein Inducers

Suppliers and Packaging for NDA: 021548

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LEXIVA
fosamprenavir calcium
 TABLET;ORAL 021548 NDA REMEDYREPACK INC. 49349-811 49349-811-02 30 TABLET, FILM COATED in 1 BLISTER PACK (49349-811-02)
LEXIVA
fosamprenavir calcium
 TABLET;ORAL 021548 NDA ViiV Healthcare Company 49702-207 49702-207-18 60 TABLET, FILM COATED in 1 BOTTLE (49702-207-18)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 700MG BASE
Approval Date:Oct 20, 2003TE:ABRLD:Yes
Patent:6,436,989*PEDPatent Expiration:Jun 24, 2018Product Flag?Substance Flag?Delist Request?Y
Patent:6,514,953*PEDPatent Expiration:Jan 15, 2020Product Flag?Substance Flag?Delist Request?Y


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Harvard Business School
Chinese Patent Office
US Army
Cerilliant
Baxter
Express Scripts
Cipla
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Related Products from thinkBiotech
Links

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot